BriaCell Therapeutics Corp. develops novel immunotherapies for cancer, with a company focus on metastatic and advanced breast cancer. Its recurring news centers on Bria-IMT™, the lead cell-based immunotherapy evaluated with an immune checkpoint inhibitor in the Bria-ABC study, and on the Bria-OTS™ and Bria-OTS+™ personalized off-the-shelf immunotherapy platforms.
Company updates also cover FDA clearance activity for Bria-BRES+™, additions of clinical trial sites, presentations at oncology meetings such as ASCO, AACR and SABCS, and biomarker, survival, quality-of-life and tolerability data from breast cancer studies. BriaCell news frequently ties its clinical programs to metastatic breast cancer populations with limited prior treatment options.
BriaCell Therapeutics (BCTX) presented pooled clinical biomarker findings linking post-treatment blood-marker measurements with survival outcomes in metastatic breast cancer.
The prospective analysis included 111 patients from multiple immunotherapy studies, including the earlier Phase 1/2 Bria-IMT study; some patients received Bria-IMT combinations. Researchers measured PD-L1, an immune-related protein, on circulating cancer-associated macrophage-like cells (CAMLs). At approximately 37 days, CAML PD-L1 was significantly associated with progression-free survival, meaning time without disease progression, but not overall survival. At approximately three months, it was significantly associated with both measures. Baseline CAML PD-L1 and pretreatment tumor PD-L1 scores of 10 or greater showed no significant survival associations. BriaCell says further studies are needed to validate CAML PD-L1 as a predictive biomarker.
BriaCell Therapeutics (BCTX) and its majority-owned subsidiary BriaPro will present four preclinical research posters at SITC on November 6–7, 2026.
The Society for Immunotherapy of Cancer annual meeting runs November 4–8 in Phoenix, Arizona. BriaCell’s poster covers its Bria-OTS+ immunotherapy platform. BriaPro’s three posters cover BP-80, a soluble CD80 protein for cancer treatment; tumor-targeted checkpoint inhibitors; and engineered CD80 variants. Copies of the posters will be available on BriaCell’s scientific publications webpage after presentation.
BriaCell Therapeutics (BCTX) reported that an independent Data Safety Monitoring Board (DSMB) issued its seventh consecutive positive recommendation for the pivotal Phase 3 Bria-ABC study evaluating Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer (NCT06072612). Following review of clinical data, the DSMB noted no safety or other clinical concerns and advised that the trial continue without modifications. DSMB meetings are held quarterly under the study protocol. The ongoing Phase 3 trial is being conducted under FDA Fast Track designation, which the company states reflects the substantial unmet medical need in metastatic breast cancer. BriaCell describes this DSMB outcome as a milestone in advancing its novel immunotherapy approach for patients with urgent unmet needs.
BriaCell Therapeutics (BCTX) has added Memorial Sloan Kettering Cancer Center as a site in its ongoing pivotal Phase 3 Bria-IMT™ plus immune checkpoint inhibitor trial for metastatic breast cancer (NCT06072612).
The study now includes more than 80 active clinical sites across 15 U.S. states, including major centers such as Penn Medicine’s Abramson Cancer Center, Mayo Clinic, Northwestern University and Yale’s Smilow Cancer Hospital. The randomized Bria-ABC study compares the Bria-IMT combination with physician’s choice of treatment, with overall survival as the primary endpoint and an interim analysis planned after 144 deaths. The trial recently received a positive recommendation from an independent DSMB to continue, follows positive Phase 2 survival data presented at ASCO 2026, holds FDA Fast Track designation, and was highlighted in Nature Medicine as one of “Eleven clinical trials that will shape medicine in 2026.” MSK has institutional financial interests related to BriaCell.
BriaCell (Nasdaq: BCTX) reported that Bria-MEL+™, its personalized whole-cell melanoma immunotherapy vaccine candidate, has passed a key genetic engineering milestone, moving the program toward potential clinical development. Bria-MEL+ is a cell-based, genetically modified, off-the-shelf cancer vaccine designed to harness a patient’s immune system against melanoma.
The approach uses a simple saliva test to HLA-match patients to one of several premanufactured cell lines, aiming to provide personalized treatment without individualized manufacturing. Bria-MEL+ builds on BriaCell’s Bria-OTS+™ platform and complements its pipeline, including Bria-IMT™ in a pivotal Phase 3 metastatic breast cancer trial, Bria-OTS™ in breast cancer, and Bria-PROS+™ in prostate cancer, which recently received FDA clearance to begin clinical evaluation. BriaCell has started development activities to support Bria-MEL+ production for potential clinical use.
BriaCell Therapeutics (Nasdaq: BCTX) received U.S. FDA clearance of its Investigational New Drug (IND) application for Bria-PROS+™, enabling initiation of a Phase 1/2a clinical study in prostate cancer. Bria-PROS+ is a next-generation, personalized, off-the-shelf, cell-based immunotherapy designed to activate multiple components of the immune system.
According to BriaCell, preclinical data showed activation of adaptive and innate immune responses, including naïve T cells, dendritic cells and NK cells. In August 2025, the program was awarded a $2 million non-dilutive grant from the U.S. National Cancer Institute to support manufacturing and planned clinical evaluation.
BriaCell (Nasdaq: BCTX) announced that Sunnybrook’s Odette Cancer Centre in Toronto has joined its ongoing pivotal Phase 3 Bria-ABC trial of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer (NCT06072612). This is BriaCell’s first Canadian clinical site, adding to over 80 active U.S. sites across 15 states.
The randomized study compares the Bria-IMT combination to physician’s treatment of choice, with overall survival as the primary endpoint and an interim analysis planned after 144 patient deaths. According to BriaCell, the trial continues following a positive DSMB recommendation, builds on positive Phase 2 survival data presented at ASCO 2026, has FDA Fast Track designation, and was highlighted in Nature Medicine as one of “Eleven clinical trials that will shape medicine in 2026.”
BriaCell Therapeutics (Nasdaq: BCTX) announced a manufacturing arrangement with FUJIFILM Biotechnologies California, a cell-therapy CDMO, to provide capacity for the remainder of BriaCell’s pivotal Phase 3 study and potential future commercial supply of Bria-IMT, an off-the-shelf allogeneic cell therapy for metastatic breast cancer.
BriaCell Therapeutics (Nasdaq: BCTX) engaged Charles River Associates and Kaleio to support commercial strategy, market access evaluation, and brand planning for its lead candidate Bria-IMT in metastatic breast cancer. Bria-IMT is in an ongoing pivotal Phase 3 study and is not yet commercially approved.
BriaCell (Nasdaq:BCTX) signed a non-binding Memorandum of Understanding with Netherlands-based Uneedle to support scalable, intradermal administration of its lead Phase 3 candidate Bria-IMT for metastatic breast cancer.
The MoU plans commercial-scale production of Uneedle’s proprietary microneedle devices, already used in Bria-IMT’s pivotal Phase 3 study, contingent on future regulatory approvals.